Robert Friesen

2019 - 2022 CSO (Chief Scientific Officer), Kiadis Pharma
2018 - 2019 Chief Scientific Officer, Ablynx
2016 - 2018 Senior Vice President Science and Early Development, ProQR Therapeutics N.V.
2014 - 2016 VP and Global Head, Biologics Research, Janssen BioTherapeutics at Janssen R&D, Janssen Pharmaceutical Companies of Johnson & Johnson
2008 - 2014 Deputy Scientific Director, Vice President Preclinical and Clinical Research, Crucell Vaccine Institute, a Johnson & Johnson Company
2005 - 2008 Head Preclinical & Early Clinical Development, MorphoSys AG
2003 - 2005 Vice President Research & Preclinical Development, AM-Pharma
2000 - 2003 Project Leader, Biomade Technolgy Foundation
1997 - 1999 Postdoctoral fellow, Universiteit van Groningen

Is dit uw profiel en heeft u vragen, opmerkingen of wijzigingen? Neem dan contact met ons op.

Robert Friesen zal vanaf 1 augustus 2021 als chief scientific officer bij Pharming Group NV starten.